Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling

Frontiers in Oncology

Volumn 3 DEC, Issue , 2013, Pages

  Foehrenbacher, Annika ^a   Secomb, Timothy W ^b   Wilson, William R ^a   Hicks, Kevin O ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Bystander effect; Extravascular drug transport; Hypoxia activated prodrugs; Pharmacokinetic pharmacodynamic modeling; PR 104; Rational drug design; Tirapazamine; Tumor hypoxia

Indexed keywords

HYPOXIA ACTIVATED PRODRUG; PRODRUG; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CELL SURVIVAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; HUMAN; HYPOXIA; MAXIMUM PLASMA CONCENTRATION; OXYGENATION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84892420818     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00314     Document Type: Article

References (92)

1. Graaf MM, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. Beta-glucuronidase-mediated drug release. Curr Pharm Des (2002) 8:1391-403. doi: 10.2174/1381612023394485.
2. Jamieson D, Wilson K, Pridgeon S, Margetts JP, Edmondson RJ, Leung HY, et al. NAD (P) H: quinone oxidoreductase 1 and NRH: quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH: quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Clin Cancer Res (2007) 13:1584. doi:10.1158/1078-0432.CCR-06-1416.
3. Bagshawe KD. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Rev Anticancer Ther (2006) 6:1421-31. doi:10.1586/14737140.6.10.1421.
4. Duarte S, Carle G, Faneca H, de Lima MC, Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now? Cancer Lett (2012) 324:160-70. doi:10.1016/j.canlet.2012.05.023.
5. Lehouritis P, Springer C, Tangney M. Bacterial-directed enzyme prodrug therapy. J Control Release (2013) 170:120-31. doi:10.1016/j.jconrel.2013.05.005.
6. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res (1998) 58:1408-16.
7. Rauth AM, Melo T, Misra V. Bioreductive therapies: an overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys (1998) 42:755-62. doi:10.1016/S0360-3016(98)00302-2.
8. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Des (1998) 13:519-28.
9. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem (2001) 8:739-61. doi:10.2174/0929867013372959.
10. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer (2004) 4:437-47. doi:10.1038/nrc1367.
11. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med (2009) 9:442-58. doi:10.2174/156652409788167087.
12. Brown M, Henry S. Kaplan distinguished scientist award lecture 2007. The remarkable yin and yang of tumour hypoxia. Int J Radiat Biol (2010) 86:907-17. doi:10.3109/09553002.2010.492492.
13. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 11:393-410. doi:10.1038/nrc3064.
14. Wilson WR, Hicks KO, Wang J, Pruijn FB. Prodrug strategies for targeting tumour hypoxia. In: Melillo G, editor. Hypoxia and Cancer: Biological Implications and Therapeutic Opportunities. New York: Springer (2013). 283 p.
15. Hay MP, Hicks KO, Wang J. Hypoxia directed drug strategies to target the tumour microenvironment. In: Koumenis C, Hammond E, Giaccia A, editors. Tumour Microenvironment and Cellular Stress. New York: Springer (2014). 111 p.
16. Haffty BG, Wilson LD, Son YH, Cho EI, Papac RJ, Fischer DB, et al. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys (2005) 61:119-28. doi:10.1016/j.ijrobp.2004.07.730.
17. Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M, et al. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res (2008) 14:7110-5. doi:10.1158/1078-0432.CCR-08-0483.
18. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 28:2989-95. doi:10.1200/JCO.2009.27.4449.
19. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (2007) 19:427-42. doi:10.1016/j.clon.2007.03.006.
20. Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, et al. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology (2011) 80:50-6. doi:10.1159/000327739.
21. Borad MJ, Reddy S, Uronis H, Sigal DS, Cohn AL, Schelman WR, et al. Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer (Abstract LB-121). AACR Annual Meeting, Chicago (2012).
22. Jameson MB, McKeage MJ, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, et al. Final results of a phase Ib trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, in combination with gemcitabine or docetaxel in patients with advanced solid tumors [abstract]. J Clin Oncol (2010) 28:2554.
23. McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, et al. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer (2011) 11:432. doi:10.1186/1471-2407-11-432.
24. McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, et al. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. BMC Cancer (2012) 12:496. doi:10.1186/1471-2407-12-496.
25. Arana Yi GY, Borthakur G, Thall PF, Coveler AL, Ravandi F, Jabbour E, et al. Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia. J Clin Oncol (2013) 31(Suppl):7074.
26. Smaill JB, Jaiswal JK, Abbattista MR, Lu G-L, Anderson RF, Ashoorzadeh A, et al. Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966. Mol Cancer Ther (2011) 10:A247. doi:10.1158/1535-7163.TARG-11-A247.
27. Yin J, Glaser R, Gates KS. On the reaction mechanism of tirapazamine reduction chemistry: unimolecular N-OH homolysis, stepwise dehydration, or triazene ring-opening. Chem Res Toxicol (2012) 25:634-45. doi:10.1021/tx200546u.
28. Shinde SS, Maroz A, Hay MP, Patterson AV, Denny WA, Anderson RF. Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). J Am Chem Soc (2010) 132:2591-9. doi:10.1021/ja908689f.
29. Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res (2007) 167:625-36. doi:10.1667/RR0807.1.
30. Hicks KO, Siim BG, Pruijn FB, Wilson WR. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors. Radiat Res (2004) 161:656-66. doi:10.1667/RR3178.
31. Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, et al. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys (2007) 69:560-71. doi:10.1016/j.ijrobp.2007.05.049.
32. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res (2010) 16:4946-57. doi:10.1158/1078-0432.CCR-10-1439.
33. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res (2007) 13:3922-32. doi:10.1158/1078-0432.CCR-07-0478.
34. Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther (2012) 11:740-51. doi:10.1158/1535-7163.MCT-11-0634.
35. Foehrenbacher A, Patel K, Abbattista M, Guise CP, Secomb TW, Wilson WR, et al. The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104. Front Oncol (2013) 3:263. doi:10.3389/fonc.2013.00263.
36. Taylor YC, Rauth AM. Oxygen tension, cellular respiration, and redox state as variables influencing the cytotoxicity of the radiosensitizer misonidazole. Radiat Res (1982) 91:104-23. doi:10.2307/3575819.
37. Koch CJ. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res (1993) 53:3992-7.
38. Siim BG, Atwell GJ, Wilson WR. Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br J Cancer (1994) 70:596-603. doi:10.1038/bjc.1994.357.
39. Whillans DW, Hunt JW. A rapid-mixing comparison of the mechanisms of radiosensitization by oxygen and misonidazole in CHO cells. Radiat Res (1982) 90:126-41. doi:10.2307/3575801.
40. Koch CJ, Stobbe CC, Bump EA. The effect on the Km for radiosensitization at 0 degree C of thiol depletion by diethylmaleate pretreatment: quantitative differences found using the radiation sensitizing agent misonidazole or oxygen. Radiat Res (1984) 98:141-53. doi:10.2307/3576058.
41. Denny WA, Wilson WR. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev (1993) 12:135-51. doi:10.1007/BF00689806.
42. Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol (2000) 163:50-9. doi:10.1006/taap.1999.8834.
43. Thurman RG, Ji S, Matsumura T, Lemasters JJ. Is hypoxia involved in the mechanism of alcohol-induced liver injury? Fundam Appl Toxicol (1984) 4:125-33. doi:10.1016/0272-0590(84)90112-X.
44. Koch CJ, Lord EM, Shapiro IM, Clyman RI, Evans SM. Imaging hypoxia and blood flow in normal tissues. Adv Exp Med Biol (1997) 428:585-93. doi:10.1007/978-1-4615-5399-1_83.
45. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal (2007) 9:1221-35. doi:10.1089/ars.2007.1628.
46. Parliament MB, Wiebe LI, Franko AJ. Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells. Br J Cancer (1992) 66:1103-8. doi:10.1038/bjc.1992.418.
47. Stewart FA, Denekamp J, Randhawa VS. Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. Br J Cancer (1982) 45:869-77. doi:10.1038/bjc.1982.139.
48. Evans SM, Schrlau AE, Chalian AA, Zhang P, Koch CJ. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J Invest Dermatol (2006) 126:2596-606. doi:10.1038/sj.jid.5700451.
49. Parmar K, Mauch P, Vergilio J, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A (2007) 104:5431-6. doi:10.1073/pnas.0701152104.
50. Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, et al. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol (2013) 15:533-43. doi:10.1038/ncb2730.
51. Guise CP, Abbattista M, Singleton RS, Holford SD, Connolly J, Dachs GU, et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res (2010) 70:1573-84. doi:10.1158/0008-5472.CAN-09-3237.
52. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, et al. Initial testing of the hypoxia activated prodrug PR-104 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 57:443-53. doi:10.1002/pbc.22921.
53. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res (2012) 18:758-70. doi:10.1158/1078-0432.CCR-11-1980.
54. Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst (2006) 98:1118-28. doi:10.1093/jnci/djj306.
55. Hicks KO. Introducing drug transport early in the design of hypoxia selective anticancer agents using a mathematical modelling approach. In: D'Onofrio A, Cerrai P, Gandolfi A, editors. New Challenges for Cancer Systems Biomedicine. Milan: Springer (2012). p. 337-54. doi:10.1007/978-88-470-2571-4_18.
56. Secomb TW, Hsu R, Park EY, Dewhirst MW. Green's function methods for analysis of oxygen delivery to tissue by microvascular networks. Ann Biomed Eng (2004) 32:1519-29. doi:10.1114/B:ABME.0000049036.08817.44.
57. Pries AR, Cornelissen AJ, Sloot AA, Hinkeldey M, Dreher MR, Hoepfner M, et al. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol (2009) 5:e1000394. doi:10.1371/journal.pcbi.1000394.
58. Secomb TW, Alberding JP, Hsu R, Dewhirst MW, Pries AR. Angiogenesis: an adaptive dynamic biological patterning problem. PLoS Comput Biol (2013) 9:e1002983. doi:10.1371/journal.pcbi.1002983.
59. Panthananickal A, Hansch C, Leo A. Structure-activity relationships in antitumor aniline mustards. J Med Chem (1978) 21:16-26. doi:10.1021/jm00199a004.
60. Helsby NA, Wheeler SJ, Pruijn FB, Palmer BD, Yang S, Denny WA, et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem Res Toxicol (2003) 16:469-78. doi:10.1021/tx025662b.
61. Gu Y, Guise CP, Patel K, Abbattista MR, Li J, Sun X, et al. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice. Cancer Chemother Pharmacol (2011) 67:543-55. doi:10.1007/s00280-010-1354-5.
62. Gu Y, Atwell GJ, Wilson WR. Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs and humans. Drug Metab Dispos (2010) 38:498-508. doi:10.1124/dmd.109.030973.
63. Patel K, Lewiston D, Gu Y, Hicks KO, Wilson WR. Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 856:302-11. doi:10.1016/j.jchromb.2007.06.035.
64. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 49:6449-65.
65. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol (2004) 14:198-206. doi:10.1016/j.semradonc.2004.04.008.
66. Wangsa-Wirawan ND, Linsenmeier RA. Retinal oxygen: fundamental and clinical aspects. Arch Ophthalmol (2003) 121:547-57. doi:10.1001/archopht.121.4.547.
67. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 8:193-204. doi:10.1038/nrc2342.
68. Patterson AV, Donate F, Jamieson S, Thompson A, Lu GL, Lee HH, et al. Pre-clinical characterization of a novel hypoxia-activated irreversible pan-HER inhibitor which induce complete responses in the H1975 xenograft model [abstract]. J Thorac Oncol (2010) 5(6):S249-S50.
69. Bagshawe KD. Antibody-directed enzyme/prodrug therapy (ADEPT). Biochem Soc Trans (1990) 18:750-2.
70. Bagshawe KD, Sharma SK, Springer CJ, Rogers GT. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. Ann Oncol (1994) 5:879-91.
71. Hay MP, Pchalek K, Pruijn FB, Hicks KO, Siim BG, Anderson RF, et al. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity. J Med Chem (2007) 50:6654-64. doi:10.1021/jm701037w.
72. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst (1997) 89:480-7. doi:10.1093/jnci/89.7.480.
73. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res (2002) 62:1425-32.
74. Atwell GJ, Yang S, Pruijn FB, Pullen SM, Hogg A, Patterson AV, et al. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5 mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. J Med Chem (2007) 50:1197-212. doi:10.1021/jm061062o.
75. Butler J, Hoey BM. The one-electron reduction potential of several substrates can be related to their reduction rates by cytochrome P-450 reductase. Biochim Biophys Acta (1993) 1161:73-8. doi:10.1016/0167-4838(93)90198-Z.
76. Cenas N, Anusevicius Z, Bironaite D, Bachmanova GI, Archakov AI, Ollinger K. The electron transfer reactions of NADPH: cytochrome P450 reductase with nonphysiological oxidants. Arch Biochem Biophys (1994) 315:400-6.
77. Pruijn FB, Patel K, Hay MP, Wilson WR, Hicks KO. Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters. Aust J Chem (2008) 61:687-93. doi:10.1071/CH08240.
78. Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion in tumors. Neoplasia (1999) 1:197-207. doi:10.1038/sj.neo.7900037.
79. Moreno-Merlo F, Nicklee T, Hedley DW. Association between tissue hypoxia and elevated non-protein sulphydryl concentrations in human cervical carcinoma xenografts. Br J Cancer (1999) 81:989-93. doi:10.1038/sj.bjc.6690797.
80. Vukovic V, Nicklee T, Hedley DW. Multiparameter fluorescence mapping of nonprotein sulfhydryl status in relation to blood vessels and hypoxia in cervical carcinoma xenografts 10. Int J Radiat Oncol Biol Phys (2002) 52:837-43. doi:10.1016/S0360-3016(01)02716-X.
81. Cardenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res (2008) 68:5812-9. doi:10.1158/0008-5472.CAN-07-6387.
82. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 8:425-37. doi:10.1038/nrc2397.
83. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res (2009) 172:653-65. doi:10.1667/RR1926.1.
84. Dewhirst MW, Kimura H, Rehmus SW, Braun RD, Papahadjopoulos D, Hong K, et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl (1996) 27:S247-51.
85. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res (1996) 56:5522-8.
86. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW, Dewhirst MW. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res (2006) 66:2219-23. doi:10.1158/0008-5472.CAN-03-2958.
87. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer (2000) 83:1589-93. doi:10.1054/bjoc.2000.1564.
88. Tietze LF, Schmuck K. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GEPT and PMT. Curr Pharm Des (2011) 17:3527-47. doi:10.2174/138161211798194459.
89. Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, et al. The macrophage-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther (2000) 7:255-62. doi:10.1038/sj.gt.3301058.
90. Ahn GO, Brown M. Targeting tumors with hypoxia-activated cytotoxins. Front Biosci (2007) 12:3483-501. doi:10.2741/2329.
91. Carlson DJ, Keall PJ, Loo BW Jr., Chen ZJ, Brown JM. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys (2011) 79:1188-95. doi:10.1016/j.ijrobp.2010.10.007.
92. Patel K, Choy SF, Hicks KO, Melink TJ, Holford NHG, Wilson WR. A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol (2011) 67:1145-55. doi:10.1007/s00280-010-1412-z.